クロストリディオイドス・ディフィシル感染 の 治療 に 関する 進歩
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。このレビューは,再発を予防することに焦点を当てて,クロストリディオイドス・ディフィシル感染 (CDI) の管理を詳細に説明します. 初期,再発,小児CDIのガイドラインを比較し,治療結果における抗生物質メカニズムと耐性を評価しています.
科学分野
- 感染症
- 微生物学
- 薬理学について
背景
- クロストリディオイドス・ディフィシル感染 (CDI) の管理は進化し,再発性感染症の予防に重点を置いています.
- CDIの病原性と抗菌剤耐性を理解することは 効果的な治療戦略に不可欠です
研究 の 目的
- 初発性,再発性,急発性,小児性CDIの治療に関する現在のガイドラインを比較する.
- CDIに対する利用可能な抗生物質の作用機構と臨床的有用性を評価する.
- CDI治療の新たな治療法を探求する
主な方法
- CDI治療に関する現在の臨床ガイドラインの体系的なレビュー.
- 抗生物質の作用機構とC. difficileにおける耐性パターンの分析
- CDI管理における新薬と補助療法の役割の評価
主要な成果
- 過去10年間でCDIの管理に重大な変化があり,再発防止を重視しています.
- バンコミシン,フィダキソミシン,メトロニダゾールに対する複雑な耐性メカニズムが特定されました.
- トキシンBに対するチゲサイクリン,リファキシミン,およびモノクローナル抗体は,補助療法としての可能性を示しています.
結論
- 現在のCDIの治療ガイドラインでは,再発を予防することが優先されています.
- 抗生物質耐性が問題となり 治療法を慎重に選択する必要があります
- 新種の抗生物質と補助的な治療法は 将来のCDIの管理に有望な道を示しています
関連する概念動画
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Strictureplasty
Proctocolectomy or total colectomy with ileostomy
Restorative proctocolectomy with Ileal pouch-anal anastomosis